<DOC>
	<DOCNO>NCT02446613</DOCNO>
	<brief_summary>This study evaluate duration effect GSK2245035 allergic reactivity repeat nasal allergen challenge ( NAC ) approximately one year treatment subject TL7116958 . This single centre , single period study subject respiratory allergy/allergies complete study TL7116958 2014 investigate long term effect previous treatment GSK2245035 compare placebo total nasal symptom elicit nasal allergen challenge . Subjects staff remain blind treatment receive TL7116958 study ( GSK2245035 placebo ) . The study consist screen visit ass eligibility criterion , study period consist single visit nasal allergen challenge perform , follow phone clinic visit discretion investigator 4-7 day follow allergen challenge . Eligible subject participate study approximately70 day total screening follow .</brief_summary>
	<brief_title>Follow-up Study Investigate Effect GSK2245035 Nasal Allergic Reactivity Subjects Completing Treatment Study TL7116958</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Adult subject allergic rhinitis complete study TL7116958 2014 . Healthy determine investigator medically qualify designee base brief physical examination . Males nonpregnant female . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Unresolved respiratory tract infection ( RTI ) time study visit 2 NAC . Investigator discretion use regard RTIs resolve 4 week precede study visit 2 . Unresolved asthma exacerbation require hospitalization and/or treatment oral steroid high dos inhale steroid time study visit 2 NAC . Investigator discretion use regard exacerbation resolve since screen visit . A change medical history since completion study TLR7116958 opinion investigator GlaxoSmithKline ( GSK ) medical monitor may pose additional risk factor . Subjects history treatment allergenspecific immunotherapy since completion TL7116958 study ; subject take investigational drug , opinion investigator designee , would effect nasal allergen challenge Subjects use steroid treatment ( nasal steroid , 4 week ; oral steroid , 4 week ; inhale steroid , 4 week ) allergic rhinitis and/or asthma prior study visit 2 , nasal allergen challenge Subjects use antihistamine ( nasal antihistamine , 48 hour ; oral antihistamine 72 hour ) , decongestant ( nasal decongestant , 24 hour ; oral decongestant , 24 hour . ) , prior study visit 2 , nasal allergen challenge . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Nasal allergen challenge</keyword>
	<keyword>Allergic Asthma</keyword>
	<keyword>Effect Allergen Reactivity</keyword>
</DOC>